Turning Point's New CEO Held the Guide, Filed a Second PMTA, and Stopped Talking About the Promo War
Modern Oral is now half the company and still doubling. So why is the EBITDA line falling 41% and the stock 53% off its February high?
TPB · Earnings Call · 2026-11-09
The guide that would not move
David Glazek's first call as CEO opened with the sort of biography that buys patience — fourteen years around the company, four as executive chairman — and then delivered the number that had already cost shareholders 10% on September 21: full-year Modern Oral net sales of $260–270 million, gross sales of $330–350 million, adjusted EBITDA of $70–80 million, all unchanged from the late-September update. Three separate analysts asked the same question in different clothes. Eric Des Lauriers noted the Modern Oral net revenue guide implies Q4 sequentially "from a slight decrease to a slight increase." Ian Zaffino asked whether seasonality or slotting fees explained it. Gerald Pascarelli asked what gets you to the high versus low end of EBITDA. The answer each time was a variation on “nothing is changing in what we're seeing with the Modern Oral business... we don't have a lot of additional transparency since then” — David Glazek, Chief Executive Officer (CEO) · 2026-11-09. That is the tension. This is a company that has made a habit of raising guidance — in May it lifted Modern Oral net sales by roughly $30 million and gross by $60 million on the back of spring chain wins. Now, with Q3 net sales up 103% year-over-year and Modern Oral at 49% of consolidated revenue versus 31% a year ago, the guide sits still. Holding a number after a history of raising it is itself information.What the new CEO actually added
The genuinely new material on this call was regulatory, not commercial. Glazek revealed the company is running a two-track PMTA process, exploiting FDA guidance issued in May that opened a secondary pathway: “we are prepping a second PMTA submission... We will list U.S. manufacturing in that PMTA submission” — David Glazek, Chief Executive Officer (CEO) · 2026-11-09. The logic is elegant — altering the manufacturing site inside the original filing risks the FDA demanding re-tests on product from a new line, so PMTA 1 stays clean in the queue while PMTA 2 carries Louisville. That reframes the entire U.S. manufacturing timeline. It was never a capex story; it is a queue-position story, which is why management still won't put a date on 2027. It also explains why PMTA submission tops this quarter's keyword set and secondary pathway appears for the first time — the forward-looking language on this call is regulatory and shelf-related, not demand-related. Note the persistence: PMTA 1 and the spring reset both recur, the latter now framed as the window when ALP's newly-won chain conversations convert.The silence where the promo war used to be
Here is the contrast that matters most. For at least four straight quarters, Turning Point's calls were dominated by competitive promotion. In August 2025: “since the category became competitive... we've seen consistent promotion from one manufacturer to the next quarter-to-quarter” — Graham A. Purdy, Chief Executive Officer · 2025-08-06. In November 2025, Graham Purdy was blunt: “Q3 was a brutal promotional quarter, but not for us” — Graham Purdy, Chief Executive Officer · 2025-11-05 — and predicted it would persist because three balance-sheet-rich majors have no choice but to spend.This quarter, the word promotional barely appears. In its place is a thesis of consolidation: “fewer players, some of the smaller guys getting weeded out, and both FRE and ALP really being surviving brands that make it to the other side of that moat” — David Glazek, Chief Executive Officer (CEO) · 2026-11-09. The keywords corroborate the shift — promotional environment and large competitor, both top-ten themes in 2025Q3, have fallen out of the company's keyword set entirely, while handful of brands and "ubiquitously distributed" enter. That is either a genuine regime change in the nicotine pouch category or the sound of a challenger that has stopped paying to play. The honest read: both. FRE and ALP are now deployed enough that shelf placement substitutes for price promotion, and the 49% revenue mix gives them a reason to prefer the narrative where the war is ending.I don't anticipate that the landscape will lighten up anytime soon from a promotional standpoint. It's been going on for over a year now. There has been some large company in the space that has been on promotion at some point in time for well over a year now.